| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JHEP.2013.12.018 |
| P698 | PubMed publication ID | 24378529 |
| P50 | author | Christophe Cassinotto | Q85271875 |
| P2093 | author name string | Jean-Baptiste Hiriart | |
| Victor de Lédinghen | |||
| Juliette Foucher | |||
| Maylis Capdepont | |||
| Julien Vergniol | |||
| Wassil Merrouche | |||
| Faiza Chermak | |||
| Le Bail Brigitte | |||
| P433 | issue | 5 | |
| P921 | main subject | steatosis | Q1365091 |
| P304 | page(s) | 1026-1031 | |
| P577 | publication date | 2013-12-28 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations | |
| P478 | volume | 60 |
| Q37632267 | A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. |
| Q41415101 | A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis. |
| Q92269846 | Adaptation of controlled attenuation parameter (CAP) measurement depth in morbidly obese patients addressed for bariatric surgery |
| Q41517362 | Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases. |
| Q43163566 | Atherosclerosis is associated with a higher risk of hepatic steatosis in HIV-infected patients |
| Q92328365 | Berberis aristata, Elaeis guineensis and Coffea canephora Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial |
| Q48339011 | Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. |
| Q33886948 | Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease |
| Q37409370 | Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients |
| Q47849653 | Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan |
| Q57782399 | Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy |
| Q54760091 | Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? |
| Q37741824 | Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population |
| Q90223674 | Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis |
| Q42610151 | Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease |
| Q41456415 | Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography |
| Q35932326 | Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score |
| Q55045481 | Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease. |
| Q64065840 | Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis |
| Q91951321 | Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial |
| Q30412738 | Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques |
| Q48121039 | Fatty liver allografts are associated with primary graft non-function and high mortality after transplantation |
| Q37674134 | Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study |
| Q93141085 | Fibroscan |
| Q36334151 | High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. |
| Q51011840 | High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance. |
| Q48217549 | Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. |
| Q37257281 | Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. |
| Q94546478 | In vivo Ultrafast Quantitative Ultrasound and Shear Wave Elastography Imaging on Farm-Raised Duck Livers during Force Feeding |
| Q41094423 | Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis. |
| Q40096029 | Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. |
| Q58740258 | Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease |
| Q87339765 | Is liver stiffness measurement to stage fibrosis in patients with nonalcoholic fatty liver disease ready for clinical use? |
| Q60909758 | Liver Fat Content and Body Fat Distribution in Youths with Excess Adiposity |
| Q37587062 | Liver Illness and Psychiatric Patients |
| Q47935849 | Liver Steatosis and Fibrosis in OSA patients After Long-term CPAP Treatment: A Preliminary Ultrasound Study |
| Q57818077 | Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations |
| Q37482466 | Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness |
| Q40444861 | Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease |
| Q39170830 | Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). |
| Q92900970 | New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode |
| Q38932554 | Non-alcoholic fatty liver disease in 2016. |
| Q24563068 | Non-alcoholic fatty liver disease: what the clinician needs to know |
| Q30427485 | Non-invasive diagnosis of alcoholic liver disease |
| Q38991269 | Non-invasive diagnosis of hepatic steatosis. |
| Q38494198 | Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives |
| Q30366569 | Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. |
| Q49884186 | Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials |
| Q38430909 | Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms |
| Q42695154 | Nonalcoholic fatty liver disease: Evolving paradigms. |
| Q55402878 | Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. |
| Q38635589 | Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)). |
| Q38772737 | Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? |
| Q30249400 | Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis |
| Q90656425 | Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis |
| Q37696026 | Pathophysiology and Management of Alcoholic Liver Disease: Update 2016. |
| Q92829495 | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
| Q91785586 | Practical Use of Transient Elastography in Screening for Nonalcoholic Steatohepatitis in a Japanese Population |
| Q40195442 | Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. |
| Q58727386 | Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study |
| Q90862928 | Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease |
| Q36658454 | Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease |
| Q34029988 | Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease. |
| Q33885985 | Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study |
| Q46476704 | Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions |
| Q41073361 | Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study |
| Q41185516 | Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. |
| Q50938841 | The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography. |
| Q37110166 | The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. |
| Q95334489 | The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter |
| Q40606091 | The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis |
| Q58597634 | The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients |
| Q33560464 | The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography |
| Q38656970 | The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis |
| Q58803093 | The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease |
| Q35784930 | Transient Elastography-Based Liver Profiles in a Hospital-Based Pediatric Population in Japan |
| Q36197572 | Transient Elastography-Based Liver Stiffness Age-Dependently Increases in Children |
| Q28079445 | Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? |
| Q33577504 | Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population |
| Q90437982 | Transient elastography: a novel, non-invasive method for the evaluation of liver stiffness and controlled attenuation parameter in cows |
| Q30432218 | Ultrasound in chronic liver disease |
| Q91662526 | Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis |
| Q41099769 | Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. |
| Q33584964 | Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study |
| Q104500412 | Utility of quantitative ultrasound in community screening for hepatic steatosis |
Search more.